Sinteza i biološko djelovanje novih supstituiranih derivata tiazolin-kinolina by MOSTAFA A. HUSSEIN et al.
Literature surveys indicate that quinoline derivatives possess diverse pharmacolo-
gical activities, including antimicrobial (1), antimalarial (2), antiviral (3), antitumor (4),
immunomodulatory (5), caspase-3 inhibition (6), antileishmanial (7), local anesthetic (8),
antiarrhythmic (8) and anti-inflammatory activities (9). Also, thiosemicarbazones consti-
tute one of the most versatile classes of compounds possessing a wide spectrum of activ-
ities. It has been reported that thiosemicarbazone derivatives possess antimicrobial (1,
10), antimalarial (11), antiamoebic (12) and antitumor (13) activities. They have been in
the focus of interest of medicinal chemists in the past decades because of the outstand-
ing biological activities exhibited by several derivatives incorporating the heterocyclic
moiety. Similarly, it is well documented that thiazoline nucleus is associated with a vari-
365
Acta Pharm. 59 (2009) 365–382 Original research paper
10.2478/v10007-009-0033-8





OLA MOHAMED F. ABOU-GHADIR
Department of Pharmaceutical Organic
Chemistry, Faculty of Pharmacy
Assiut University, Assiut-71526, Egypt
Accepted July 31, 2009
5-Acyl-8-hydroxyquinoline-2-(3’-substituted-4’-aryl-2,3-
-dihydrothiazol-2’-ylidene)hydrazones, 5a-e to 10a-c, were
prepared by the reaction of appropriate 5-acyl-8-hydro-
xyquinoline-4-substituted thiosemicarbazones 3a-e and
phenacyl bromides 4a-e. Structures of the new compounds
were verified on the basis of spectral and elemental analy-
ses. Twenty-eight new compounds were tested for their
possible antimicrobial activities. Most of the tested com-
pounds showed weak to moderate antibacterial activity
against most of the bacterial strains used in comparison
with gatifloxacin as a reference drug. The test compounds
showed weak to moderate antifungal activity against te-
sted fungi in comparison with ketoconazole as a referen-
ce drug. On the other hand, the newly synthesized com-
pounds were tested for their anti-inflammatory effects and
most of them showed good to excellent anti-inflamma-
tory activity compared to indomethacin. Moreover, ulce-
rogenicity and the median lethal dose (LD50) of the most
active anti-inflammatory compounds 6b and 9e were de-
termined in mice; they were non-toxic at doses up to 400
mg kg–1 after i.p. administration.
Keywords: quinoline, thiosemicarbazone, thiazoline, phe-
nacyl bromide, antimicrobial, anti-inflammatory
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ety of pharmacological actions, including antimicrobial (10), anti-inflammatory (14), anti-
tumor (15) and antioxidant (16) actions.
Accordingly, the present work is aimed at the design and synthesis of new thiazo-
-line quinoline compounds derived by cyclization of quinoline thiosemicarbazone. More-




Melting points were determined on an electrothermal melting point apparatus (Stu-
art Scientific, SMP1, UK) and were uncorrected. Pre-coated silica gel plates (Kieselgel
0.25 mm, 60G F254, Merck, Germany) were used for TLC to monitor the reactions using
CHCl3/CH3OH 9:1 as the mobile phase. Visualization of the spots was effected using an
ultraviolet lamp (model CM-10, Spectroline, USA) and/or iodine stain.
IR spectra were carried out as KBr discs on a Shimadzu IR-470 Spectrometer (Shi-
madzu, Japan). 1H NMR spectra were scanned on a Varian EM-360L NMR spectrometer
(60 MHz, Varian, USA). Chemical shifts are expressed in d-values (ppm) relative to tetra-
methylsilane (TMS) as an internal standard using CDCl3 as solvent; deuterium oxide was
used for the detection of exchangeable protons.
Mass spectra were recorded with a JEOL JMS600 mass spectrometer (JEOL, Japan).
Elemental microanalyses were performed on a Perkin-Elmer 240 Elemental Analyzer
(Perkin-Elmer, USA).
Syntheses
The starting materials 5-acyl-8-hydroxyquinolines 1a and 1b (1) and the intermedi-
ates, 4-substituted-3-thiosemicarbazides 2a-e (17), 5-acyl-8-hydroxy-quinoline-4-substi-
tuted thiosemicarbazones 3a-f (1), and phenacyl bromides 4a-e (18) were prepared ac-
cording to reported procedures.
5-Acetyl-8-hydroxyquinoline-2-(3’-substituted-4’-aryl-2,3-dihydrothiazol-2’-ylidene)-
-hydrazones (5a-e to 8a-e) and 5-benzoyl-8-hydroxyquinoline-2-(3’-cyclohexyl-4’-
-aryl-2,3-dihydrothiazol-2’-ylidene)hydrazones (10a-c)
A solution of the appropriate thiosemicarbazone derivative 3a-d and 3f (0.0015 mol),
anhydrous sodium acetate (100 mg, 0.0012 mol) and the appropriate phenacyl bromide
4a-e (0.0015 mol) in absolute ethanol (30 mL) was heated under reflux for 12-24 h, con-
centrated and left overnight. The product was filtered, dried and crystallized from absolute
ethanol (Scheme 1, Tables I and II).
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A solution of the thiosemicarbazone derivative 3e (0.504 g, 0.0015 mol), anhydrous
sodium acetate (100 mg, 0.0012 mol) and the appropriate phenacyl bromide 4a-e (0.0015
mol) in absolute ethanol (30 mL) was stirred at room temperature for 10-15 h, concen-
trated and left overnight. The product was filtered, dried and crystallized from absolute
ethanol (Scheme 1, Tables I and II).
Antimicrobial activity
Antibacterial activity. – The synthesized compounds 5a-e to 10a-c were tested for their
antibacterial activity in vitro in comparison with gatifloxacin as a reference drug using
the standard agar disc diffusion method (19) against six bacterial species: Bacillus cereus
(AUMC B70), Staphylococcus aureus (AUMC B71) and Micrococcus luteus (AUMC B68) as
representatives of the Gram-positive strains, while the Gram-negative strains were rep-
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R: CH3 or C6H5
R1: CH3, C2H5, CH2CH=CH2, cyclo-C6H11 or C6H5
R2: H, Br, Cl, CH3 or OCH3
Scheme 1
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1H NMR (CDCl3, d ppm)
a
5a –
10.23 (d, 1H, H2 of quinoline); 9.47 (d,1H, H4 of quinoline);
8.47–7.63 (m, 9H, OH, H3,6,7 of quinoline, C6H5); 6.42 (s, 1H,
CH of thiazoline); 3.7 (s, 3H, NCH3); 2.83 (s, 3H, CH3)
5b
452 [M+] (63.3 %),
170 [M+] (100 %),
454 [M++2] (71.9 %)
10.63 (d, 1H, H2 of quinoline); 9.72 (d,1H, H4 of quinoline);
8.57–7.75 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.60 (s, 1H,
CH of thiazoline); 3.70 (s, 3H, NCH3); 2.80 (s, 3H, CH3)
5c –
10.73 (d, 1H, H2 of quinoline); 9.8 (d,1H, H4 of quinoline);
8.5–7.8 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.53 (s, 1H,
CH of thiazoline); 3.72 (s, 3H, NCH3); 2.82 (s, 3H, CH3)
5d –
10.57 (d, 1H, H2 of quinoline); 9.7 (d, 1H, H4 of quinoline);
8.73–7.88 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.56 (s, 1H,
CH of thiazoline); 3.73 (s, 3H, NCH3); 2.83 (s, 3H, CH3); 2.63
(s,3H, C6H4-CH3)
5e –
10.25 (d, 1H, H2 of quinoline); 9.5 (d, 1H, H4 of quinoline);
8.4–7.37 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.33 (s, 1H,
CH of thiazoline); 4.13 (s, 3H, OCH3); 3.60 (s, 3H, NCH3);
2.82 (s, 3H, CH3)
6a –
10.57 (d, 1H, H2 of quinoline); 9.70 (d, 1H, H4 of quinoline);
8.67–7.40 (m, 9H, OH, H3,6,7 of quinoline, C6H5); 6.63 (s, 1H, CH
of thiazoline); 4.40 (q, 2H, NCH2); 2.70 (s, 3H, CH3); 1.30 (t,
3H, -N-CH2CH3)
6b –
10.67 (d, 1H, H2 of quinoline); 9.73 (d, 1H, H4 of quinoline);
8.57–7.77(m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.50 (s, 1H,
CH of thiazoline); 4.27 (q, 2H, NCH2); 2.83 (s, 3H, CH3); 1.40
(t, 3H, -N-CH2CH3)
6c
422 [M+] (54.2 %),
170 [M+] (100 %),
424 [M++2] (23.7 %)
10.37 (d, 1H, H2 of quinoline); 9.60 (d, 1H, H4 of quinoline);
8.33–7.57(m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.30 (s, 1H,
CH of thiazoline); 4.17 (q, 2H, NCH2); 2.80 (s, 3H, CH3); 1.37 (t,
3H, -N-CH2CH3)
6d –
10.50 (d, 1H, H2 of quinoline); 9.73 (d, 1H, H4 of quinoline);
8.42–7.63 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.30 (s, 1H,
CH of thiazoline); 4.23 (q, 2H, NCH2); 2.80 (s, 3H, CH3); 2.60
(s,3H, C6H4-CH3); 1.38 (t, 3H, -N-CH2CH3)
6e –
10.67 (d, 1H, H2 of quinoline); 9.73 (d, 1H, H4 of quinoline);
8.43–7.33 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.33 (s, 1H,
CH of thiazoline); 4.26 (q, 2H, NCH2); 4.13 (s, H, C6H4-OCH3);
2.83 (s, 3H, CH3); 1.432 (t, 3H, -N-CH2CH3)
7a 400 [M+] (100 %)
10.5 (d, 1H, H2 of quinoline); 9.73 (d,1H, H4 of quinoline);
8.93–7.67 (m, 9H, OH, H3,6,7 of quinoline, C6H5);7.00–6.00 (m,
1H, CH=CH2); 6.5 (s, 1H, CH of thiazoline); 5.9–5.33 (dd,
2H, CH=CH2); 4.92 (d, 2H, NCH2); 2.90 (s, 3H, CH3)
7b –
10.33 (d, 1H, H2 of quinoline); 9.58 (d,1H, H4 of quinoline);
8.6–7.7 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 7.00–6.00 (m,
1H, CH=CH2); 6.53 (s, 1H, CH of thiazoline); 5.93–5.33 (dd,
2H, CH=CH2); 4.9 (d, 2H, NCH2); 2.83 (s, 3H, CH3)
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7c
434 [M+] (100 %),
436 [M++2] (36.1 %)
10.33 (d, 1H, H2 of quinoline); 9.53 (d,1H, H4 of quinoline);
8.47–7.63 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.80–6.00 (m,
1H, CH=CH2); 6.50 (s, 1H, CH of thiazoline); 5.80–5.16 (dd,
2H, CH=CH2); 4.80 (d, 2H, NCH2); 2.73 (s, 3H, CH3)
7d –
10.17(d, 1H, H2 of quinoline); 9.40 (d,1H, H4 of quinoline);
8.53–7.37 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.63–6.1
(m, 1H, CH=CH2); 6.30 (s, 1H, CH of thiazoline); 5.70–5.16
(dd, 2H, CH=CH2); 4.7 (d, 2H, NCH2); 2.73 (s, 3H, CH3); 2.53
(s, 3H, C6H4CH3)
7e –
10.30 (d, 1H, H2 of quinoline); 9.50 (d,1H, H4 of quinoline);
8.56–7.4 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.93–6.23 (m,
1H, CH=CH2); 6.4 (s, 1H, CH of thiazoline); 5.9–5.33 (dd, 2H,
CH=CH2); 4.86 (d, 2H, NCH2); 4.23 (s, 3H, OCH3); 2.86 (s,
3H, CH3)
8a –
10.20 (d, 1H, H2 of quinoline); 9.33 (d,1H, H4 of quinoline);
8.70–7.37 (m, 9H, OH, H3,6,7 of quinoline, C6H5); 6.20 (s, 1H,
CH of thiazoline); 4.33–3.67 (m, 1H, NCH of cyclohexyl); 2.77
(s, 3H, CH3); 3.34–0.13 (m, 10H, (CH2)5 of cyclohexyl)
8b
520 [M+] (14.8 %),
55 [M+] (100 %),
522 [M++2] (14.9 %)
10.17 (d, 1H, H2 of quinoline); 9.40 (d,1H, H4 of quinoline);
8.37–7.53 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.27 (s, 1H,
CH of thiazoline); 4.30–3.63 (m, 1H, NCH of cyclohexyl); 2.80
(s, 3H, CH3); 3.47–0.80 (m, 10H, (CH2)5 of cyclohexyl)
8c –
10.23 (d, 1H, H2 of quinoline); 9.40 (d,1H, H4 of quinoline);
8.40–7.40 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.27 (s, 1H,
CH of thiazoline); 4.37–3.07 (m, 1H, NCH of cyclohexyl); 2.80
(s, 3H, CH3); 3.40–0.80 (m, 10H, (CH2)5 of cyclohexyl)
8d –
10.30 (d, 1H, H2 of quinoline); 9.47 (d,1H, H4 of quinoline);
8.37–7.60 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.27 (s, 1H,
CH of thiazoline); 4.50–3.80 (m, 1H, NCH of cyclohexyl);
2.83 (s, 3H, CH3); 2.60 (s, 3H, C6H4CH3); 3.50–0.80 (m, 10H,
(CH2)5 of cyclohexyl)
8e –
10.30 (d, 1H, H2 of quinoline); 9.53 (d,1H, H4 of quinoline);
8.50–7.40 (m, 8H, OH, H3,6,7 of quinoline, C6H4); 6.27 (s, 1H,
CH of thiazoline); 4.18 (s, 3H, OCH3); 4.47–3.80 (m, 1H, NCH of
cyclohexyl); 2.85 (s, 3H, CH3); 3.53–0.83 (m, 10H, (CH2)5 of cy-
clohexyl)
9a –
10.30 (d, 1H, H2 of quinoline); 9.60 (d,1H, H4 of quinoline);
8.50–7.60 (m, 14H, OH, H3,6,7 of quinoline, NC6H5, C6H5);
6.70 (s, 1H, CH of thiazoline); 2.63 (s, 3H, CH3)
9b –
10.23 (d, 1H, H2 of quinoline); 9.43 (d,1H, H4 of quinoline);
8.40–7.40 (m, 13H, OH, H3,6,7 of quinoline, NC6H5, C6H4);
6.63 (s, 1H, CH of thiazoline); 2.63 (s, 3H, CH3)
9c
470 [M+] (100 %),
472 [M++2] (38.7 %)
10.17 (d, 1H, H2 of quinoline); 9.43 (d,1H, H4 of quinoline);
8.28–7.38 (m, 13H, OH, H3,6,7 of quinoline, NC6H5, C6H4); 6.60
(s, 1H, CH of thiazoline); 2.60 (s, 3H, CH3)
9d –
10.25 (d, 1H, H2 of quinoline); 9.50 (d,1H, H4 of quinoline);
8.37–7.43 (m, 13H, OH, H3,6,7 of quinoline, NC6H5, C6H4);
6.37 (s, 1H, CH of thiazoline); 2.60 (s, 3H, CH3); 2.43 (s, 3H,
C6H4CH3)
resented by Escherichia coli (AUMC B69), Pseudomonas aeruginosa (AUMC B72), and Serra-
tia marcescens (AUMC B67).
Cell suspension of bacterial strains was prepared from 48-h old cultures on nutrient
agar (NA) in sterile water. One milliliter of suspension was added to a Petri dish of 9 cm
diameter and then 15 mL of NA was poured into the plate. The plate was shaken gently
to homogenize the inocula.
Sterile 5-mm filter paper disc (Whatman, UK) was saturated with 10 mL of the solu-
tion of test compound and gatifloxacin as a reference drug (53 mmol mL–1 in DMSO). In
addition, an other disc was impregnated with the solvent (DMSO) and served as a nega-
tive control. The discs were then dried for 1 h and placed in the center of each plate. The
seeded plates were incubated at 35 ± 2 °C for 24–48 h. The radii of inhibition zones (in
mm) of triplicate sets were measured and the results are given in Table III.
Antifungal activity. – The synthesized compounds 5a-e to 10a-c were tested for their
antifungal activity in vitro in comparison with ketoconazole as a reference drug using
the standard agar disc diffusion method (19). Seven pathogenic [Trichophyton rubrum (Cas-
tellani) Sabouraud AUMC 1145, and Candida albicans (Robin) Berkhout AUMC 421], phy-
topathogenic (Fusarium oxysporum Schlechtendal AUMC 208) and food deteriorating
fungal species [Aspergillus flavus Link AUMC 3372, Aspergillus niger Van Tieghem AUMC
3364, Geotrichum candidum Link AUMC 228, and Scopulariopsis brevicaulis (Saccardo) Bai-
nier AUMC 363] were used in the study.
Spore suspension in sterile distilled water was prepared from a 2–5 days old culture
of the test fungi grown on Sabouraud agar (SA) media. The final spore concentration
was nearly 5 × 104 spores mL–1. About 15 mL of growth medium was added to sterilized
Petri dishes of 9 cm diameter and inoculated with 1 mL of spore suspension. Plates were
shaken gently to homogenize the inocula.
Sterile 5-mm filter paper disc (Whatman) was saturated with 10 mL of test compound
solution and ketoconazole (40 mmol mL–1 in DMSO). In addition, another disc was im-
pregnated with DMSO and served as a negative control. The discs were then dried for 1 h
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9e –
10.20 (d, 1H, H2 of quinoline); 9.47 (d,1H, H4 of quinoline);
8.37–7.10 (m, 13H, OH, H3,6,7 of quinoline, NC6H5, C6H4); 6.50
(s, 1H, CH of thiazoline); 4.03 (s, 3H, OCH3); 2.60 (s, 3H, CH3)
10a –
9.67 (d, 1H, H2 of quinoline); 8.70 (d,1H, H4 of quinoline);
8.73–7.70 (m, 14H, OH, H3,6,7 of quinoline, 2 C6H5); 6.33 (s,
1H, CH of thiazoline); 3.90–3.23 (m, 1H, NCH of cyclohexyl);
2.60–0.23 (m, 10H, (CH2)5 of cyclohexyl)
10b –
9.40 (d, 1H, H2 of quinoline); 8.80–7.43 (m, 14H, OH, H3,4,6,7
of quinoline, C6H5, C6H4); 6.23 (s, 1H, CH of thiazoline);
4.20–3.13 (m, 1H, NCH of cyclohexyl); 2.40–0.53 (m, 10H,
(CH2)5 of cyclohexyl)
10c
538 [M+] (54.6 %),
247 [M+] (100 %),
540 [M++2] (23.7 %)
9.47 (d, 1H, H2 of quinoline); 8.90–7.57 (m, 14H, OH, H3,4,6,7 of
quinoline, C6H5, C6H4); 6.33 (s, 1H, CH of thiazoline); 4.13–3.23
(m, 1H, NCH of cyclohexyl); 2.63–0.67 (m, 10H, (CH2)5 of cy-
clohexyl)
a Proton of OH is exchangeable with D2O.
and placed in the center of each plate. The seeded plates were incubated at 28 ± 2 °C for
7 days. The radii of inhibition zones (in mm) of triplicate sets were measured at succes-
sive intervals during the incubation period and the results are given in Table IV.
Anti-inflammatory activity
Male adult albino rats (120–150 g) and mice (25–30 g) were obtained from the ani-
mal house (Faculty of Medicine, Assiut University, Egypt). Animals were housed in sepa-
rate cages 6 animals each, in temperature-controlled rooms at 25 °C. Animals were al-
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Table III. Antibacterial activity of compounds 5a-e to 10a-c and gatifloxacina
Inhibition zone (mm)
Compd.a Gram-positive Gram-negative
B. cereus S. aureus M. luteus E. coli P. aeroginosa S. marcescens
5a 9 – – – – –
5b 9 – – 10 – 30
5c 18 – – – – 22
5e 12 – – 18 – 10
6a 12 – – – – 7
6b 8 – – – – 14
6c 13 – – – – 14
6d 8 – – – – –
6e 12 – – – – 9
7a 8 – – 14 – –
7b 10 – – 16 – 15
7c 7 – – – – –
7d – – – 12 12 –
7e – – – – – 7
8a – 10 – 12 – –
8b – 12 – 12 8 –
8c 7 – – 10 – 24
8d – 12 – – 10 –
8e 7 – – – – –
9a 10 – – – – 20
9b 13 – – – – 23
9c 14 – – – – 15
10c 10 – – – 10 –
Gatifloxacin 34 30 19 30 24 34
(–) – no inhibition
a 53 mmol mL–1 in DMSO
lowed free access to rodent chow and water and maintained at a 12 h light/dark cycle.
Work was conducted in accordance with the internationally accepted principles for labo-
ratory animals’ use and care as found in the European Community Guidelines (20) and
Institutional Ethical Committee Approval was obtained.
Indomethacin (Liometacin® vial, Nile Company, Egypt), carrageenan (Sigma, USA),
sodium carboxymethylcellulose (NaCMC) and normal saline were obtained from the lo-
cal market.
All tested compounds and the reference drug were suspended in 1 % NaCMC in
normal saline. Suspensions of the tested compounds, reference drug and 1 % NaCMC-
-saline solution (negative control) were injected i.p. (1 mL each).
The anti-inflammatory activity of the newly synthesized compounds 5a-e to 10a-c
together with the intermediate compounds 3a-f was evaluated according to the carra-
geenan induced paw edema method in comparison with indomethacin as a reference drug
(21). The test is based on pedal inflammation in rat paws induced by subplantar injec-
tion of carrageenan suspension (0.2 mL of 1 % solution in normal saline) into the right
hind paw of the rats. Male adult albino rats were divided into groups of four animals
each. The rat paw thickness was measured with a Vernier caliper (SMIEC, China) before
and 1 h after carrageenan injection to detect the carrageenan induced inflammation. Each
tested compound, at a dose of 0.02 mmol kg–1, was injected i.p. to thirty four different
groups of rats 1 h after carrageenan injection. Control group received the vehicle (1 %
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Table IV. Antifungal activity of test compounds 5a-e to 10a-c and ketoconazolea
Inhibition zone (mm)
Compd. T. rubrum C. albicans F. oxysporum A. flavus A. niger G. candidum S. brevicaulis
5a – – 10 20 18 – –
5b – – 12 10 15 10 –
5c – – 13 20 18 15 10
5e – 8 13 20 20 12 –
6a – – 10 12 10 – 9
6b – – 9 – 13 – 10
6c – – – 10 12 – 9
6e – – 12 15 10 – 10
7b – – 10 – 12 – 9
8c – 9 10 8 18 10 7
8e – – – 7 – – –
9a – – – 10 – – 20
9b – – – 13 – – 23
9c – – – 14 – – 15
Ketoconazole – 32 8 34 24 32 –
(–) – no inhibition
a 40 mmol mL–1 in DMSO
sodium carboxymethylcellulose (NaCMC) solution in normal saline), while the reference
group received indomethacin i.p. at a dose of 0.02 mmol kg–1.
The difference between the thicknesses of the two paws was taken as a measure of
edema. The measurement was carried out at 0, 0.5, 1, 2, 3, 4 and 5 h after injection of the
tested compounds, reference drug and control. The results are listed in Table V.
Gastric ulceration
Ulcerogenicity of the most active anti-inflammatory compounds 6b and 9e was de-
termined on male adult albino rats according to a reported method (22).
Gastric lesions on the mucosa were determined using a stereoscopic microscope (XJP-
-XSC-195-40X, Jiangsu, China). Observation of gastrointestinal mucosa for the presence
of lesions following oral administration of graded doses of the tested compounds as
well as the reference drug was taken as an indication of ulcerogenic effects. Both the fre-
quency of ulceration (expressed as the ratio of ulcerated animals) and the severity of ul-
ceration (expressed as the ulcer index) were used for comparison of the tested com-
pounds and indomethacin. Male albino rats were fasted for 24 h. Compounds 6b, 9e and
indomethacin were administered orally at doses of 10, 30, and 50 mg kg–1 as suspensions
in a 1 % NaCMC-saline solution to groups of rats of 6 animals each. After 6 h, the ani-
mals were sacrificed, the stomachs were removed and gastric lesions on the mucosa
were determined using a stereoscopic microscope. Ulcer was defined as at least one le-
sion of 0.5 mm or more in length. All lesions of more than 0.1 mm in length were
summed up to obtain the ulcer index and the results are listed in Table VI.
Acute toxicity
The median lethal dose (LD50) of the most active and safe compounds (6b and 9e)
was determined in mice (23). Groups of male adult albino mice of four animals each,
were injected i.p. with graded doses of the tested compounds. The percentage mortality
in each group of animals was determined 72 h after the injection.
Partitioning data
The log P values of the tested compounds 5a-e to 10a-c were computed by a routine
method called calculated log P (Clog P) (contained in the PC-software package McLogP
2.0, BioByte Corp., CA, USA, Table I). The molecular structure is entered into the pro-




thiazol-2’-ylidene) hydrazones 5a-e to 8a-e and 10a-c were prepared by refluxing the ap-
propriate 5-acyl-8-hydroxyquinoline-4-substituted thiosemicarbazones 3a-d and 3f and
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phenacyl bromides 4a-e in the presence of anhydrous sodium acetate in absolute etha-
nol. The 5-acetyl-8-hydroxyquinoline-2-(3’-phenyl-4’-aryl-2,3-dihydrothiazol-2’-ylidene)
hydrazones 9a-e were prepared by stirring 5-acetyl-8-hydroxyquinoline-4-phenyl thio-
semicarbazone 3e with appropriate phenacyl bromide 4a-e in ethanol at room tempera-
ture. Structures of the target compounds 5a-e to 10a-c were confirmed by IR, 1H NMR, MS
in addition to elemental analysis. IR spectra of compounds 5a-e to 10a-c were character-
ized by a lack of characteristic bands of NH and NCS functional groups and exhibited a
band attributed to C=N stretching at 1634–1562 cm–1. Moreover, all compounds showed the
characteristic band at 3545–3410 cm–1 (OH stretching of 8-hydroxyquinoline) in addition
to its bending at 769–650 cm–1. 1H NMR spectra of the prepared products (Table II)
showed a general pattern for the 8-hydroxyquinoline characterized by the presence of
two doublet signals at 10.17–10.73 ppm and at 9.33–9.80 ppm corresponding to H-2 and
H-4 of quinoline, respectively, a multiplet at 7.10–8.93 ppm corresponding to the phenyl
group, the OH group (exchangeable), and H-3, H-6 and H-7 of quinoline, a singlet signal
at 6.20–6.70 ppm corresponding to the thiazoline proton, and a singlet signal at 2.60–2.90
ppm corresponding to CH3, in addition to the disappearance of signals corresponding to
the N2-H and N4-H signals. Also, the structure of the target compounds was confirmed
by MS of representative compounds 5b, 6c, 7a, 7c, 8b, 9c and 10c. MS for compound 5b
revealed the molecular ion peak M+ at m/z 452 (63.3 %) corresponding to the relative mo-
lecular mass of this compound (452.03) and a base peak at m/z 170 (100 %). It also
showed the M++2 peaks of 81Br and the 34S peak at m/z 454 (71.9 %). MS for compound
6c revealed the molecular ion peak M+ at m/z 422 (54.2 %) corresponding to the Mr of
this compound (422.10) and a base peak at m/z 170 (100 %). It also showed the M++2
peak of 37Cl and the 34S peak at m/z 424 (23.7 %). MS for compound 7a revealed the molec-
ular ion peak M+ at m/z 400 (100 %) corresponding to the Mr of this compound (400.14),
which is also the base peak. MS for compound 7c revealed the molecular ion peak M+ at
m/z 434 (100 %) corresponding to the Mr of this compound (434.10), which is also the
base peak. It also showed the M++2 peak of 37Cl peak at m/z 436 (36.1 %). MS for com-
pound 8b revealed the molecular ion peak M+ at m/z 520 (14.8 %) corresponding to the
Mr of this compound (520.09) and a base peak at m/z 55 (100 %). It also showed the M++2
peak of 81Br peak at m/z 522 (14.9 %). MS for compound 9c revealed the molecular ion
peak M+ at m/z 470 (100 %) corresponding to the Mr of this compound (470.10), which is
also the base peak. It also showed the M++2 peak of 37Cl peak at m/z 472 (38.7 %). MS for
compound 10c revealed the molecular ion peak M+ at m/z 538 (54.6 %) corresponding to
the Mr of this compound (538.16) and a base peak at m/z 247 (100 %). It also showed the
M++2 peak of 37Cl peak at m/z 540 (23.7 %).
Antimicrobial activity
Results of the antibacterial activity (Table III) indicated that M. luteus was comple-
tely resistant to the tested compounds, while B. cereus, E. coli and S. marcescens were the
most sensitive organisms to the tested compounds.
Compounds 5d, 9d, 9e, 10a and 10b were completely inactive against the tested or-
ganisms. Also the test compounds were most inactive against S. aureus and P. aeroginosa
except for compounds 7d, 8a, 8b, 8d and 10c. On the other hand, tested compounds
were active against B. cereus, E. coli and S. marcescens since they showed 20–88 % antibac-
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terial activity of that exerted by gatifloxacin. The most active compounds were 5b, 5c,
5e, 7b, 8c, 9a and 9b. The latter contain Cl, Br or OCH3 as an R2 substituent. It was also
noticed that the introduction of a phenyl group in compounds 9a-e resulted in a de-
crease of their antibacterial activity. Also, the cyclohexyl substituent at R1 seems to be
crucial for the antibacterial activity.
Results of antifungal activity (Table IV) revealed that all the tested compounds were
inactive against T. rubrum. They were also inactive against C. albicans, except for com-
pounds 5e and 8c and against G. candidum, except for compounds 5b, 5c, 5e, and 8c
which showed 31–47 % activity compared to ketoconazole. Several compounds showed
weak to moderate activity against S. brevicaulis, while the reference drug was completely
inactive. Important to say, compounds 5a-c, 5e, 6a, 6b, 6e, 7b and 8c were even more ac-
tive than ketoconazole against F. oxysporum. The most active compounds were 5c, 6e, 7b,
8c and 9b comprising Cl, Br or OCH3 as an R2 substituent.
Anti-inflammatory activity
Results of anti-inflammatory activity (Table V) revealed that all the tested com-
pounds showed a gradual increase of anti-inflammatory activity up to its maximum af-
ter 4 h. After 5 h, almost all the newly synthesized compounds showed 51–78 % edema
inhibition (edema inhibition of indomethacin at the time is 80.9 %). Accordingly, com-
parison between the tested compounds was made at the moment of the highest activity.
Compounds 3a-f, 5a-e, 6a-e, 7a-e, 8a-e, 9a-e and 10 a-c showed 63–104 % of the anti-in-
flammatory activity of indomethacin after 4 h.
It is noteworthy that cyclization of thiosemicarbazone derivatives 3a-f into the cor-
responding thiazoline derivatives 5a-e to 10a-c resulted in a marked increase of anti-in-
flammatory activity, which is similar to previous findings (21). Also, most of the com-
pounds bearing p-Cl, p-Br, or p-OCH3 substituents on the phenyl group showed high
anti-inflammatory activity indicating the crucial role of halogen or OCH3 for anti-infla-
mmatory activity, which is similar to previous data (25).
Ulcerogenic effect and acute toxicity
The most active anti-inflammatory compounds 6b and 9e and indomethacin were
evaluated for their ulcerogenic effect (Table VI). Data revealed that compounds 6b and
9e had no ulcerogenic effect at the treating doses of 10 and 30 mg kg–1 while at higher
doses (50 mg kg–1) they exhibited lower ulcerogenic activity compared to indomethacin.
Indomethacin caused ulceration at the tested dose levels and increased in frequency and
severity at higher doses.
In addition, the median lethal doses (LD50) of compounds 6b and 9e were evaluated
and it was found that they were non-toxic at doses up to 400 mg kg–1 (i.p.) while the re-
ported LD50 of indomethacin is 13 mg kg–1 (i.p.) (26).
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Table V. Inhibitory effect of test compounds 5a-e to 10a-c and indomethacina upon carrageenan induced
paw edema in rats
Compd.a
Edema inhibition (%)
0 h 0.5 h 1 h 2 h 3 h 4 h 5 h
3a 4.4 30.9 42.5 50.2 56.5 52.9 50.2
3b 7.4 31.2 35.0 39.7 47.3 47.6 47.6
3c 3.7 31.0 31.0 43.2 44.0 47.5 39.1
3d 3.7 31.2 31.2 39.7 50.4 58.8 61.6
3e 4.7 30.85 34.73 39.42 53.33 58.55 55.75
3f 4.4 26.9 30.9 35.8 47.0 58.6 55.8
5a 2.2 31.2 31.2 39.7 59.9 61.6 44.8
5b 4.4 30.9 30.9 43.0 59.6 66.9 64.1
5c 3.5 46.4 50.2 61.0 69.1 69.7 66.9
5d 2.2 38.9 38.9 43.3 63.0 55.9 53.2
5e 2.2 23.3 38.8 43.2 56.6 64.2 57.7
6a 5.6 31.0 46.5 50.4 53.5 55.9 50.3
6b 8.2 46.7 58.3 64.9 69.3 78.3 69.9
6c 7.1 50.2 57.9 61.0 69.1 72.5 72.5
6d 8.1 38.8 42.6 46.8 56.6 58.7 53.1
6e 8.1 34.9 54.3 61.2 66.0 61.5 55.9
7a 4.4 38.6 42.5 50.2 56.5 58.6 52.9
7b 4.7 42.8 50.5 57.7 65.7 61.6 55.9
7c 2.0 42.6 42.6 46.8 56.6 72.6 69.8
7d 3.7 31.0 38.8 57.6 56.6 50.3 50.3
7e 3.5 30.9 38.6 46.6 56.5 72.5 69.9
8a 4.5 31.0 42.6 46.8 59.8 67.0 69.8
8b 2.0 38.6 42.5 50.2 69.1 72.5 69.7
8c 4.4 38.8 34.9 46.6 56.5 66.9 69.7
8d 4.7 38.8 34.9 46.8 62.9 69.8 72.6
8e 3.9 31.2 42.8 54.1 66.2 75.5 69.9
9a 2.2 31.2 31.2 39.7 53.6 61.6 64.4
9b 1.8 31.0 38.8 46.8 62.9 67.0 61.5
9c 2.0 42.5 42.5 50.2 69.1 72.5 69.9
9d 3.7 31.0 31.0 39.6 53.5 61.5 55.9
9e 4.7 42.8 46.7 61.3 72.5 75.5 69.9
10a 7.1 34.7 46.4 50.2 72.2 75.3 75.3
10b 7.9 38.6 50.2 64.6 69.1 72.5 78.1
10c 7.4 27.3 38.9 54.1 53.6 58.8 53.2
Negative control – – – – – – –
Indomethacin 7.9 42.5 61.9 64.6 72.2 75.3 80.9
a 0.02 mmol kg–1 in 1 % NaCMC solution in normal saline
CONCLUSIONS
A number of 5-acyl-8-hydroxyquinoline-2-(3’-substituted-4’-aryl-2,3-dihydro-thiazol-
-2’-ylidene)hydrazones, 5a-e to 10a-c, were prepared and tested for their antibacterial ac-
tivities. They showed moderate activity against most of the tested bacterial strains but
showed no antibacterial activity against M. luteus. The antifungal data of the tested com-
pounds showed that the N-methyl and N-ethyl series were the most active compounds
and many compounds showed better antifungal activity against F. oxysporum than ke-
toconazole; some also showed activity against S. brevicaulis (c.f. ketoconazole). On the
other hand, the tested compounds showed a gradual increase in their anti-inflammatory
activity, reaching its maximum after 4 h in the carrageenan induced paw edema. Cycli-
zation of thiosemicarbazone derivatives into the corresponding thiazoline derivatives
resulted in a marked increase in anti-inflammatory activity. The p-bromo- p-chloro- and
p-methoxy-phenyl derivatives showed the highest activity, which indicates the crucial
role of halogen or OCH3. Compounds 6b,c, 7b,c,e, 8b,e, 9c,e, and 10a,b showed activity
comparable to that of indomethacin as the reference drug.
The most active anti-inflammatory compounds 6b and 9e were safer than indome-
thacin in ulcerogenic liability in frequency and severity. In addition, the LD50 of com-
pounds 6b and 9e showed that they were non-toxic at doses up to 400 mg kg–1 (i.p.)
whereas the LD50 of indomethacin is only 13 mg kg–1 (i.p.).
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Table VI. Ulcerogenic effect of compounds 6b, 9e and indomethacin
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S A @ E T A K
Sinteza i potencijalno biolo{ko djelovanje novih supstituiranih
derivata tiazolin-kinolina
MOSTAFA A. HUSSEIN, ABDEL-HAMID N. KAFAFY, SAMIA G. ABDEL-MOTY i OLA MOHAMED F. ABOU-GHADIR
5-Acil-8-hidroksikinolin-2-(3’-supstituirani-4’-aril-2,3-dihidrotiazol-2’-iliden) hidrazoni
5a-e do 10a-c pripravljeni su reakcijom odgovaraju}ih 5-acil-8-hidroksikinolin-4-sup-
stituiranih tiosemikarbazona 3a-e i fenacil bromida 4a-e. Strukture novih spojeva potvr-
|ene su na temelju spektralnih i elementarnih analiza. Dvadeset osam novih spojeva testi-
rano je na potencijalno antimikrobno djelovanje. Ve}ina spojeva pokazuje slabo do umje-
reno antibakterijsko djelovanje protiv ve}ine testiranih bakterijskih sojeva u usporedbi s
gatifloksacinom kao referentim lijekom, te slabo do umjereno antifungalno djelovanje pro-
tiv gljivica u usporedbi s ketokonazolom kao referentnim lijekom. Testovi na protuupal-
no djelovanje pokazuju da ve}ina spojeva posjeduje dobro ili sna`no protuupalno djelo-
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vanje u usporedbi s indometacinom. Ulcerogeno djelovanje i srednje letalne doze (LD50)
najaktivnijih spojeva 6b i 9e odre|ene su na mi{evima. Rezultati pokazuju da su netok-
si~ni u dozama do 400 mg kg–1 nakon i.p. primjene.
Klju~ne rije~i: kinolin, tiosemikarbazon, tiazolin, fenacil bromid, antimikrobno djelovanje, protuupal-
no djelovanje
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